Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-Hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

MG Symptoms PRO scores were developed by UCB1 and have not been validated in any languages for use in MG. The MG Symptoms PRO analysis was part of the planned efficacy analysis; however, efficacy or clinical significance should be interpreted with caution.

1. Cleanthous S, et al. Orphanet J Rare Dis. 2021;16:457.